The FDA cleared Fujirebio’s Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio blood test, aiming to expand access to amyloid pathology assessment for earlier decision-making in Alzheimer’s disease. The Plasma Ratio is an automated immunoassay intended for adults aged 50 and older presenting to specialized care settings with signs and symptoms of cognitive decline. The clinical utility centers on concordance between blood biomarkers and established pathology assessments such as PET imaging and cerebrospinal fluid (CSF) measurements. By using a blood draw, the test is designed to reduce reliance on expensive or invasive procedures while supporting confident clinical decisions about next steps. The article highlights that the test reports high positive and negative predictive values, intended to help clinicians identify patients likely to have underlying amyloid pathology and potentially route them toward additional evaluation, specialist referral, or disease-modifying therapy pathways. This regulatory milestone fits into the broader shift toward blood-based biomarkers (BBMs) as pragmatic tools for neurodegenerative care, particularly where access to PET and CSF testing is limited.